Proteomics could also be vital to the future of the pharmaceutical industry, says Jessica Chutter, managing director and co-director of biotechnology for Morgan Stanley.
In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.